摘要
目的探讨奥扎格雷钠联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法 70例急性脑梗死患者依据入院单双日随机分成观察组和对照组各35例。两组均给予常规综合治疗,观察组静脉滴注奥扎格雷钠联合依达拉奉;对照组静脉滴注川芎嗪联合灯盏花素,疗程均14 d。对两组患者治疗前、治疗7、14 d后的神经功能缺损情况进行评分,14 d后比较两组临床总有效率。结果与治疗前比较,两组患者治疗7、14 d后神经功能缺损评分均降低,但观察组较对照组降低更明显(P<0.05);治疗14 d后,两组临床总有效率比较,观察组优于对照组(P<0.05);两组均无明显不良反应。结论奥扎格雷钠联合依达拉奉治疗急性脑梗死与传统川芎嗪联合灯盏花素比较,临床疗效更为显著,不良反应不明显,值得临床推广使用。
Objective To investigate the clinical efficacy and safety of sodium ozagrel combined with edaravone in treating acute cerebral infarction. Methods 70 cases of acute cerebral infarction were randomly divided into the observation group and the control group according to the odd-numbered and even-numbered days at admission, 35 cases in each group. Both groups were given the conventional comprehensive treatment. The observation group used sodium ozagrel combined with edaravone by intravenous drip ,while the control group received tetramethylpyrazine combined with breviscapine by intravenous drip ,for 14 d. The neurological function deficit score before treatment, on 7,14 d after treatment was performed in the two groups .The total clinical effective rates after 14 d were compared between the two groups. Results Compared with before treatment,the neurological deficit scores after 7,14 d treatment in the two groups were decreased, but the decrease in the observation group was more signifi- cant than the control group （P〈0.05）. The total clinical effective rate after 14 d treatment in the observation group was better than that in the control group（P〈0.05）. No obvious adverse reactions ocurred in the two groups. Conclusion Compared with conventional treatment of tetramethylpyrazine combined with breviscapine, sodium ozagrel combined with edaravone has more significant clinical effect with un0bvious adverse reactions in treating acute cerebral infarction,which is worthy to be widely promoted and applied in clinic.
出处
《现代医药卫生》
2013年第4期506-507,共2页
Journal of Modern Medicine & Health
关键词
脑梗死
药物疗法
奥扎格雷钠
依达拉奉
川芎嗪
灯盏细辛
药物疗法
联合
随机对照试验
Brain infarction/drug therapy
Sodium ozagrel
Edamvone
Tetramethylpyrazine
Erigeron breviscapus
Drug therapy,combination
Randomized controlled trial
